Association for Creatine Deficiencies (ACD) Announces Addition of Dr. Andreas Schulze to Scientific Medical Advisory Board
CARLSBAD, Calif., November 21, 2017 (Newswire.com) - The Association for Creatine Deficiencies (ACD) welcomes Dr. Andreas Schulze, MD, Ph.D., who will be serving on the Scientific Medical Advisory Board, helping shape the future of CCDS research and therapy. Whitnie Strauss, ACD president, remarked, “Dr. Schulze is a world-renowned expert on creatine deficiencies and we are very excited about the contributions he will be making to ACD.”
Dr. Schulze received his MD and Ph.D. in biochemistry at the University of Leipzig, Germany. He has worked at the Hospital for Sick Children in Toronto, Canada, since 2007 and has established his own research group with a focus on Cerebral Creatine Deficiency Syndromes, Regulation of Creatine Synthesis, Pathophysiology of Guanidino Compounds and Small Molecule Treatments. He is director of the Newborn Screening Program at the Hospital for Sick Children, as well as the section head of Metabolic Genetics. Dr. Schulze remarked, “I was the first to report and describe the full biochemical spectrum in GAMT Deficiency and have an ongoing interest in advancing research of creatine deficiencies. I am glad to join my colleagues in working towards these goals with ACD.”
I was the first to report and describe the full biochemical spectrum in GAMT Deficiency and have an ongoing interest in advancing research of creatine deficiencies. I am glad to join my colleagues in working towards these goals with ACD.
Andreas Schulze, MD, PhD
About ACD: The Association for Creatine Deficiencies’ mission is to eliminate the challenges of CCDS. ACD is committed to providing patient, family and public education to advocate for early intervention through newborn screening, and to promote and fund medical research for treatments and cures for Cerebral Creatine Deficiency Syndromes (CCDS). Because CCDS mimic symptoms of other medical conditions, patients are often first diagnosed with autism, cerebral palsy, epilepsy and other disorders. Proper diagnosis and early intervention are critical to establishing screening and treatments needed to improve life quality and longevity for the CCDS patient. For more information regarding ACD, please visit http://www.creatineinfo.org.
Source: Association for Creatine Deficiencies
